Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Hank

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Hematology/Oncology Clinics of North America|October 26, 2001
Antibody-directed, effector cell-mediated tumor destructionP M Sondel, J A Hank
Advances in Experimental Medicine and Biology|January 1, 1983
Cell mediated lysis of lymphocytes expressing bacterial antigensJ A Hank, P M Sondel
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1982
Soluble bacterial antigen induces specific helper and cytotoxic responses by human lymphocytes in vitroJ A Hank, P M Sondel
Human Immunology|April 1, 1984
Recognition of autologous lymphoblastoid cells by cloned human T cells: inhibition of cytotoxicity by anti-HLA antibody but not by antibody to Epstein-Barr virus induced cell surface antigenJ A Hank, P M Sondel
Cancer Investigation|January 1, 1989
Prospects for clinical cancer treatment using interleukin-2P M Sondel, J A Hank
Transplantation Proceedings|December 1, 1981
Alien-driven diversity and alien-selected escape: a rationale for allogeneic cancer immunotherapyP M Sondel, J A Hank
The Cancer Journal From Scientific American|February 11, 1998
Combination therapy with interleukin-2 and antitumor monoclonal antibodiesP M Sondel, J A Hank
Biotherapy (Dordrecht, Netherlands)|January 1, 1991
BLT-esterase activity following in vitro and in vivo activation of human lymphocytes with interleukin-2. In vivo IL-2 induces BLT-esteraseA Cannon, J A Hank, P M Sondel
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant diseaseJ A Hank, M R Albertini, P M Sondel
Biotherapy (Dordrecht, Netherlands)|January 1, 1992
Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2M R Albertini, J A Hank, P M Sondel
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Hematology/Oncology Clinics of North America|October 26, 2001
Antibody-directed, effector cell-mediated tumor destructionP M Sondel, J A Hank
Advances in Experimental Medicine and Biology|January 1, 1983
Cell mediated lysis of lymphocytes expressing bacterial antigensJ A Hank, P M Sondel
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1982
Soluble bacterial antigen induces specific helper and cytotoxic responses by human lymphocytes in vitroJ A Hank, P M Sondel
Human Immunology|April 1, 1984
Recognition of autologous lymphoblastoid cells by cloned human T cells: inhibition of cytotoxicity by anti-HLA antibody but not by antibody to Epstein-Barr virus induced cell surface antigenJ A Hank, P M Sondel
Cancer Investigation|January 1, 1989
Prospects for clinical cancer treatment using interleukin-2P M Sondel, J A Hank
Transplantation Proceedings|December 1, 1981
Alien-driven diversity and alien-selected escape: a rationale for allogeneic cancer immunotherapyP M Sondel, J A Hank
The Cancer Journal From Scientific American|February 11, 1998
Combination therapy with interleukin-2 and antitumor monoclonal antibodiesP M Sondel, J A Hank
Biotherapy (Dordrecht, Netherlands)|January 1, 1991
BLT-esterase activity following in vitro and in vivo activation of human lymphocytes with interleukin-2. In vivo IL-2 induces BLT-esteraseA Cannon, J A Hank, P M Sondel
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant diseaseJ A Hank, M R Albertini, P M Sondel
Biotherapy (Dordrecht, Netherlands)|January 1, 1992
Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2M R Albertini, J A Hank, P M Sondel
Pageof 10